sch-22219 has been researched along with Eczema* in 5 studies
3 trial(s) available for sch-22219 and Eczema
Article | Year |
---|---|
Modrasone for the skin: worth prescribing?
Topics: Administration, Topical; Clinical Trials as Topic; Dermatitis, Seborrheic; Eczema; Humans; Methylprednisolone; Skin Diseases | 1988 |
Alcometasone dipropionate 0.05% ointment versus hydrocortisone 1.0% ointment in eczema & other dermatoses.
Topics: Administration, Topical; Adolescent; Adult; Aged; Anti-Inflammatory Agents; Child; Clinical Trials as Topic; Double-Blind Method; Eczema; Female; Humans; Hydrocortisone; Male; Methylprednisolone; Middle Aged; Ointments; Random Allocation; Skin Diseases | 1988 |
Alclometasone dipropionate 0.05% vs hydrocortisone 1.0%: potential to induce cutaneous atrophy in children.
Alclometasone dipropionate 0.05% and hydrocortisone 1.0% ointments were applied twice daily for three weeks to bilateral, paired eczematous lesions of children. Study ointments were assigned to left- and right-sided test sites in a randomized, double-blind manner. The potential of these preparations to induce clinically significant cutaneous atrophy was evaluated in 34 children by visual assessment of the test sites under magnification for telangiectasia. Efficacy was evaluated in 32 children by ratings of the severity of erythema, induration, and pruritus and global evaluations of eczema at the test sites. Safety and efficacy evaluations were performed prior to initial application of the study agents and after each week of treatment. Telangiectasia and other signs of cutaneous atrophy were not observed at any test site during the study, and treatment was well tolerated. Only one of the 34 children experienced an adverse effect: a mild, transient urticarial rash occurring with the application of both study ointments during the first week of the study. In general, the ointments were equally effective in relieving the children's signs and symptoms of eczema. After three weeks of therapy, improvement in the total score of ratings of the severity of signs and symptoms averaged 88% at alclometasone-treated sites and 86% at hydrocortisone-treated sites. Topics: Atrophy; Child; Child, Preschool; Double-Blind Method; Eczema; Female; Humans; Hydrocortisone; Male; Methylprednisolone; Ointments; Random Allocation; Skin; Telangiectasis | 1987 |
2 other study(ies) available for sch-22219 and Eczema
Article | Year |
---|---|
Corticosteroid contact allergy--the importance of late readings and testing with corticosteroids used by the patients.
Topics: Dermatitis, Allergic Contact; Dermatologic Agents; Drug Hypersensitivity; Eczema; Female; Hand Dermatoses; Humans; Hydrocortisone; Methylprednisolone; Middle Aged | 2007 |
Topical corticosteroid therapy for children: alclometasone dipropionate cream 0.05%.
The safety and efficacy of twice-daily applications of alclometasone dipropionate cream 0.05% were evaluated in 39 children with eczema during a three-week open study. Early-morning plasma cortisol levels were monitored at weekly intervals (visits 1, 2, and 3) for six children. For the remaining 33 children, levels were measured at visits 1 and 2 and two weeks later, at visit 4. Improvement in signs and symptoms of erythema, induration, and pruritus and a global response to therapy were determined weekly. Plasma cortisol levels remained within the acceptable normal range of 7 to 25 micrograms/100 ml throughout the study in all 39 children. At the conclusion of treatment, a favorable global response--complete clearing of monitored signs and symptoms--was observed in 28 (72%) children, and marked or moderate improvement was recorded for seven (18%) children. Topics: Administration, Topical; Anti-Inflammatory Agents; Child; Child, Preschool; Dermatitis, Atopic; Dermatitis, Seborrheic; Diaper Rash; Drug Evaluation; Eczema; Erythema; Humans; Hydrocortisone; Infant; Methylprednisolone; Pruritus | 1986 |